Cargando…
The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
The number of available therapies for rare diseases remains low, as fewer than 6% of rare diseases have an approved treatment option. The International Rare Diseases Research Consortium (IRDiRC) set up the multi-stakeholder Data Mining and Repurposing (DMR) Task Force to examine the potential of app...
Autores principales: | Southall, Noel T, Natarajan, Madhusudan, Lau, Lilian Pek Lian, Jonker, Anneliene Hechtelt, Deprez, Benoît, Guilliams, Tim, Hunter, Lawrence, Rademaker, Carin MA, Hivert, Virginie, Ardigò, Diego |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794821/ https://www.ncbi.nlm.nih.gov/pubmed/31615551 http://dx.doi.org/10.1186/s13023-019-1193-3 |
Ejemplares similares
-
Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients
por: Zanello, Galliano, et al.
Publicado: (2022) -
Towards the international interoperability of clinical research networks for rare diseases: recommendations from the IRDiRC Task Force
por: Nabbout, Rima, et al.
Publicado: (2023) -
Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures
por: Morel, Thomas, et al.
Publicado: (2017) -
How to START? Four pillars to optimally begin your orphan drug development
por: Jonker, Anneliene Hechtelt, et al.
Publicado: (2023) -
Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective
por: Austin, Christopher P., et al.
Publicado: (2017)